Ferguson, M., et al. Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial. Hum Vaccin Immunother, 2025 Dec, 21(1):2579335. PMID: 41194599
Respiratory syncytial virus (RSV) is a leading cause of respiratory illness across all age groups, particularly affecting infants, older adults, and individuals with chronic health conditions, [...]